Screening anti-infectious molecules against Mycobacterium ulcerans: A step towards decontaminating environmental specimens

PLoS One. 2020 Aug 6;15(8):e0231685. doi: 10.1371/journal.pone.0231685. eCollection 2020.

Abstract

Mycobacterium ulcerans, a non-tuberculous mycobacterium responsible for Buruli ulcer, resides in poorly defined environmental niches in the vicinity of stagnant water. Very few isolates have been confirmed. With a view to culturing M. ulcerans from such contaminated environmental specimens, we tested the in vitro susceptibility of the M. ulcerans CU001 strain co-cultivated with XTC cells to anti-infectious molecules registered in the French pharmacopoeia. We used a standardised concentration to identify molecules that were inactive against M. ulcerans and which could be incorporated into a decontaminating solution. Of 116 tested molecules, 64 (55.1%) molecules were ineffective against M. ulcerans CU001. These included 34 (29.3%) antibiotics, 14 (12%) antivirals, eight (6.8%) antiparasitics, and eight (6.8%) antifungals. This left 52 molecules which were active against M. ulcerans CU001. Three of the inactive antimicrobial molecules (oxytetracycline, polymyxin E and voriconazole) were then selected to prepare a decontamination solution which was shown to respect M. ulcerans CU001 viability. These three antimicrobials could be incorporated into a decontamination solution to potentially isolate and culture M. ulcerans from environmental samples.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / analysis*
  • Buruli Ulcer / microbiology
  • Colistin
  • Humans
  • Mass Screening
  • Microbial Sensitivity Tests / methods
  • Mycobacterium
  • Mycobacterium ulcerans / growth & development*
  • Mycobacterium ulcerans / isolation & purification*
  • Mycobacterium ulcerans / pathogenicity
  • Oxytetracycline
  • Voriconazole

Substances

  • Anti-Infective Agents
  • Voriconazole
  • Oxytetracycline
  • Colistin

Grants and funding

NH obtained a PhD grant from the Fondation Méditerranée Infection, Marseille, France. https://www.mediterranee-infection.com/linstitut/infectiopole-sud/ This work was supported by Agence Nationale de la Recherche (ANR-17-CE35-0006-01 PRIME, http://www.agencenationale-recherche.fr/) and by the French Government under the « Investissements d’Avenir » (Investments for the Future) program managed by the ANR (reference: Méditerranée Infection 10-IAHU-03), as well as the Agence Nationale de la Recherche (ANR-17-CE35-0006-01 PRIME, http://www.agencenationale-recherche.fr/). This work was supported by Région Provence Alpes Côte d’Azur and European funding FEDER IHUBIOTK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.